Clinical trial · Interventional
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
NCT02954796CI-TRIAL-00040001terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor decision based on portfolio prioritization
Summary
Brief summary (as posted)
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SGN-CD352A | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- (Dose Escalation) Cohort -1 - 6
- description
- SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
- interventionNames
- Drug: SGN-CD352A
Primary outcomes (2)
- measure
- Type, incidence, severity, seriousness, and relatedness of adverse events (including laboratory abnormalities)
- timeFrame
- Through 1 month following last dose.
- measure
- Incidence of dose-limiting toxicity
- timeFrame
- During Cycle 1 (Trial Days 1-28)
Secondary outcomes (8)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group \[IMWG\] ). * Age 18 years or older. * An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Life expectancy greater than 3 months. * Received at least 2 prior lines of therapy for MM including an immunomodulatory drug and a proteasome inhibitor. * Measurable disease, as defined by at least one of the following: Serum M protein 0.5 g/dL or higher, Urine M protein 200 mg/24 hr or higher, Serum free light chain (SFLC) 10 mg/dL or higher, and Abnormal SFLC ratio. * Adequate hematologic, renal, and hepatic function * A negative pregnancy test (for females of childbearing potential). * Patients must provide written informed consent. Exclusion Criteria: * Other invasive malignancy within the past 3 years. * Active cerebral/meningeal disease related to the underlying malignancy. * Active Grade 3 or higher infection. * Known to be positive for HIV or known to have active hepatitis B or C. * Previous allogeneic stem cell transplant. * Idiopathic interstitial pneumonia or impaired diffusion capacity of the lung for carbon monoxide (DLCO). * Cerebrovascular or cardiovascular event, or congestive heart failure within the last 6 months. * Females who are pregnant or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.